John Fesko Sells 663 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 663 shares of the business's stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total transaction of $117,861.51. Following the completion of the transaction, the insider now directly owns 156,044 shares of the company's stock, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

John Fesko also recently made the following trade(s):

• On Monday, December 23rd, John Fesko sold 669 shares of Natera stock. The stock was sold at an average price of $159.60, for a total transaction of $106,772.40.

Natera Stock Performance

NASDAQ:NTRA traded down $4.27 during mid-day trading on Tuesday, hitting $167.92. The company's stock had a trading volume of 669,204 shares, compared to its average volume of 1,311,706. The business's fifty day moving average is $167.71 and its two-hundred day moving average is $141.47. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera, Inc. has a 1 year low of $67.33 and a 1 year high of $183.00. The stock has a market cap of $22.17 billion, a price-to-earnings ratio of -95.40 and a beta of 1.66.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. During the same period in the prior year, the company posted ($0.95) EPS. The company's revenue for the quarter was up 63.9% on a year-over-year basis. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Creative Planning raised its holdings in Natera by 28.3% in the 2nd quarter. Creative Planning now owns 4,929 shares of the medical research company's stock valued at $534,000 after acquiring an additional 1,087 shares during the last quarter. Sanctuary Advisors LLC acquired a new stake in Natera in the 2nd quarter valued at approximately $380,000. Park Avenue Securities LLC increased its holdings in Natera by 14.7% in the 3rd quarter. Park Avenue Securities LLC now owns 7,833 shares of the medical research company's stock valued at $994,000 after purchasing an additional 1,005 shares during the last quarter. GAMMA Investing LLC increased its holdings in Natera by 32.7% in the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company's stock valued at $55,000 after purchasing an additional 106 shares during the last quarter. Finally, CWM LLC increased its holdings in Natera by 119.5% in the 3rd quarter. CWM LLC now owns 15,441 shares of the medical research company's stock valued at $1,960,000 after purchasing an additional 8,406 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Barclays started coverage on shares of Natera in a research note on Thursday, January 23rd. They issued an "overweight" rating and a $200.00 price objective for the company. Leerink Partners upped their price target on Natera from $140.00 to $150.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Piper Sandler upped their price target on Natera from $150.00 to $200.00 and gave the stock an "overweight" rating in a research report on Monday, November 18th. Canaccord Genuity Group upped their price target on Natera from $165.00 to $180.00 and gave the stock a "buy" rating in a research report on Friday, January 3rd. Finally, Sanford C. Bernstein upped their price target on Natera from $160.00 to $200.00 and gave the stock an "outperform" rating in a research report on Friday, January 10th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Natera currently has an average rating of "Moderate Buy" and a consensus target price of $165.88.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.